Takashi M, Haimoto H, Tanaka J, Murase T, Kato K
Department of Urology, Nagoya University School of Medicine, Japan.
J Urol. 1989 Apr;141(4):830-4. doi: 10.1016/s0022-5347(17)41024-x.
To evaluate whether serum gamma-enolase is a useful marker for renal cell carcinoma alpha and gamma-enolases in tissues of 36 renal cell carcinomas and 13 normal kidneys, and in sera of 103 renal cell carcinoma patients were determined with an enzyme immunoassay system. Tissue gamma and alpha-enolase levels were 34 and 2.3 times higher, respectively, in renal cell carcinoma than in normal renal cortex. The tissue gamma enolase-to-total enolase value of renal cell carcinoma (5.3 per cent) was significantly higher than that of normal cortex (0.29 per cent) and medulla (0.51 per cent). Over-all serum gamma-enolase levels were elevated (more than 6.0 ng. per ml.) in 53 of 103 patients (51 per cent) with renal cell carcinoma. In regard to stage the positive rates were 34 per cent (12 of 35) of patients with stage I, 22 per cent (2 of 9) with stage II, 80 per cent (12 of 15) with stage III, 61 per cent (22 of 36) with stage IV and 61 per cent (5 of 8) with recurrent disease. The mean value of serum gamma-enolase in renal cell carcinoma (8.0 +/- 5.7 ng. per ml.) was significantly higher than that of normal subjects (3.1 +/- 0.9 ng. per ml., p less than 0.001). The mean value of serum gamma-enolase in patients with high stage tumors (III and IV, 9.9 +/- 6.8 ng. per nl.) was significantly higher than that of low stage tumors (I and II, 5.8 +/- 3.0 ng. per ml., p less than 0.001). In 39 patients treated by complete surgical excision serum gamma-enolase was significantly reduced postoperatively (p less than 0.01). Furthermore, 7 of 8 patients whose serum gamma-enolase levels were determined serially had levels within the normal range postoperatively that increased when distant metastases appeared. These results indicate that serum gamma-enolase could be a useful tumor marker to stage disease and monitor treatment in patients with renal cell carcinoma.
为评估血清γ-烯醇化酶是否为肾细胞癌的有用标志物，采用酶免疫分析系统测定了36例肾细胞癌组织、13例正常肾组织以及103例肾细胞癌患者血清中的α-烯醇化酶和γ-烯醇化酶。肾细胞癌组织中γ-烯醇化酶和α-烯醇化酶水平分别比正常肾皮质高34倍和2.3倍。肾细胞癌组织中γ-烯醇化酶与总烯醇化酶的比值（5.3%）显著高于正常皮质（0.29%）和髓质（0.51%）。103例肾细胞癌患者中，53例（51%）的血清γ-烯醇化酶总体水平升高（超过6.0 ng/ml）。就分期而言，I期患者的阳性率为34%（35例中的12例），II期为22%（9例中的2例），III期为80%（15例中的12例），IV期为61%（36例中的22例），复发患者为61%（8例中的5例）。肾细胞癌患者血清γ-烯醇化酶的平均值（8.0±5.7 ng/ml）显著高于正常受试者（3.1±0.9 ng/ml，p<0.001）。高分期肿瘤（III期和IV期）患者血清γ-烯醇化酶的平均值（9.9±6.8 ng/ml）显著高于低分期肿瘤（I期和II期）患者（5.8±3.0 ng/ml，p<0.001）。39例接受完整手术切除治疗的患者术后血清γ-烯醇化酶显著降低（p<0.01）。此外，8例接受连续血清γ-烯醇化酶水平测定的患者中，7例术后水平在正常范围内，出现远处转移时升高。这些结果表明，血清γ-烯醇化酶可能是肾细胞癌患者疾病分期和监测治疗的有用肿瘤标志物。
